Johnson & Johnson, Explanations for Clotting ? – Part 2

We continue from Johnson & Johnson, Explanations for Clotting ?

Most immunizations are into the deltoid muscle of the upper arm.  In recent years, there has been increased interest in subcutaneous injection. This can result in more immune response with less antigen, or the reverse.  That tissue is more delicate, more susceptible to damage.  And there have been some tragic failures, when the immunization did not “take”. So whatever site is used in the clinical trials is baked into the usage.

The deltoid muscle is resistant to damage, and there is a simple “finger rule” to avoid hitting a nerve with the needle. Some muscle fibers die as a result of the injection, but they are replaced in days. The muscle has strong blood supply and high metabolic rate, which protects it from occasional bacterial pathogens.

A fraction of active material of the injection stays in muscle to “transfect” muscle cells, causing them to produce spike protein, which in turn induces immunity. Most of the injected material does not remain in place.  Muscle is so well supplied with circulation that most of the active material drains out. Another fraction drains through the lymphatic system, reaching the axial lymph nodes, in the armpit, where it may still make a contribution to immunity, if it can find suitable cells to transfect.

The remaining fraction enters the blood circulation. With a classical vaccine, consisting of inert materials, this fraction is lost; it makes no contribution to developing immunity and has no further effect on the body. The bulk of it is caught by the liver, degraded into less suspicious substances, and excreted.

We are going to accumulate Tinkertoy pieces that may be useful in building a hypothesis bridge from a place called Mystery,  to another called Prospect, spanning the River Doubt. If and when the bridge is complete, it will be a theory that can be tested. Cast a wide net at first. Keep  Occam’s Razor always within sight. Back in August 2020, I had some suspicion. There are some Tinkertoys in (CNN) More European nations pause AstraZeneca vaccine use as blood clot reports investigated, but I’m not eager to pick them up. If in the future, they make an Occam contribution, well and good; let them lie for now.

An adenovirus vaccine is not inert. Even though the vector cannot reproduce, it pries its way into cells. The fraction that enters the blood may not be benign. Adenoviruses are generally toxic to the liver; (BMJ) The promise and potential hazards of adenovirus gene therapy. Quoting,

What’s toxic about adenovirus vectors?

Much concern has focused on the direct toxic effects of adenoviruses, particularly as intravenous administration of the virus can induce acute liver injury, as shown in animal models. It is this effect which may have triggered the cascade of events leading to the death of the patient with OTC deficiency—

AstraZeneca/J&J know this well, and think they have their bases covered, with a comparatively minute quantity of vaccine reaching the liver. Maybe, maybe not. It may depend upon prior infections, which often leave live viruses, jailed, in the liver. Until something comes along with the key.

You’re probably wondering what this has to do with CVST.  We’ll get to that. To be continued shortly.



Leave a Reply